A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration
Year: 2019
Type: review
Abstract: Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly in the developed world. While treatment is effective for the neovascular or "wet" form of AMD, no therapy is successful for the non-neovascular or "dry" form. Here we discuss the current knowledge on dry AMD pathobiology and propose future research directions that would expedite the development of new treatments. In our view, these should emphasize system biology approaches that integrate omic, pharmacological, and clinical data into mathematical models that can predict disease onset and progression, identify biomarkers, establish disease causing mechanisms, and monitor response to therapy.
Source: Nature Communications
Institutions: Johns Hopkins University, Duke Medical Center, National Institute for Health and Care Research, University of Bristol, UCL Biomedical Research Centre, Moorfields Eye Hospital, University College London, University of California, Los Angeles, Massachusetts Eye and Ear Infirmary, Harvard University, University of Tübingen, Rutgers, The State University of New Jersey, Rutgers New Jersey Medical School, Boston University
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,200
Funders: U.S. Department of Health and Human Services, International Retinal Research Foundation, Research to Prevent Blindness, BrightFocus Foundation, California Institute of Regenerative Medicine, American Macular Degeneration Foundation, Louis and Harold Price Foundation, Coherus Biosciences, National Institute for Health and Care Research, Sight Research UK, European Commission, Rosetrees Trust, Moorfields Eye Hospital NHS Foundation Trust, National Institutes of Health, Genentech, Novartis Pharma, Horizon 2020 Framework Programme, Medical Research Council, National Institute on Aging, National Eye Institute, Daiichi Sankyo Europe
Awards: G1137049897, G1404592120, G2113217606, G2121942404, G2332775, Alzheimer Disease Genetic Architecture in African Americans, Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD, G4302202594, G434337789, Genetics of Age-Related Maculopathy, G4873686981, Alzheimer's Disease Genetics Consortium, G5520316217, Exploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways, G7010756571, Innate immunity, lipoproteins and AMD progression, Genomic and Biological Studies of APOE ε2 in Alzheimer Disease, Oxidative stress and innate immunity impair the visual cycle, G8370337821, G9000015130, G9000087432, P30 Core Grant for Vision Research, Center Core Grant for Vision Research
OpenAlex ID: W2964556340